R&D UPDATE

Home » R&D UPDATE
Enero 2012

The Gilead/Pharmasset Combination Increases Future Competition
* Pharmasset (VRUS), acquired for nearly $11 billion this week, will provide Gilead (GILD) with two developmental hepatitis C virus...

Diciembre 2011

Competition Starting in 2014 for Incivek and Victrelis.
Por Julie S. Hoggatt; julie.hoggatt@wolterskluwer.com / Leon Henderson; leon.henderson@wolterskluwer.com / Ben Weintraub;...

Septiembre 2011

Wolters Kluwer Script Data Tracks the Launches
Julie S. Hoggatt; julie.hoggatt@wolterskluwer.com / Leon Henderson; leon.henderson@wolterskluwer.com / Ben Weintraub;...

Julio 2011

Vemurafenib & Yervoy Have Limitations Despite Positive Trials
Marc Engelsgjerd; marc.engelsgjerd@wolterskluwer.com / David Yee; david.yee@wolterskluwer.com / Ben Weintraub;...

Julio 2011

Ipilimumab & Vemurafenib Data at Plenary Session
Marc Engelsgjerd; marc.engelsgjerd@wolterskluwer.com / David Yee; david.yee@wolterskluwer.com / Ben Weintraub;...

Mayo 2011

Platelet-Rich Plasma and Related Growth Factors Generate Excitement Julie Hoggatt; julie.hoggatt@wolterskluwer.com
PRP – The Next Big Biologic?
An off-label procedure becoming increasingly performed before resorting to orthopedic surgery is...

Enero 2011

Indication: Non-small cell lung cancer. Products: Tovok (afatinib, BIBW 2992, phase III, Boehringer Ingelheim). Vargatef (BIBF 1120, phase III, Boehringer Ingelheim). Crizotinib (phase III, Pfizer [PFE]). Probabilities of Approval: Tovok: 53%(C), Vargatef:...
• Despite the promise of kinase inhibitors, no drugs in this class have been approved for the treatment of non-small cell lung cancer...

Septiembre 2010

Predictable Caveats Should Not Derail.
Drug Name: Brilinta (ticagrelor) Developer: AstraZeneca (AZN) Indication: Acute Coronary Syndromes (ACS)

Probability...

Junio 2010

Will the Drug Outperform Warfarin? Drug Name: Apixaban (BMS 562247; BMS 562247-01) Developers: Bristol-Myers Squibb (BMY) and Pfizer (PFE) Indication: Stroke Prevention in Atrial Fibrillation (SPAF) Probability of Approval: 58%(C), increased from 40%(C)...
* Last week, the AVERROES trial, sponsored by Bristol-Myers Squibb (BMY) and Pfizer (PFE), was stopped early due to apixaban’s...

Mayo 2010

Encuesta realizada en enero de 2010. Esta encuesta pretendía identificar posibles cambios en las estrategias de ventas y marketing del sector farmacéutico en los tres últimos años, y la motivación de los cambios potenciales en un futuro próximo.
Instrumento de la encuesta
Se formularon las siguientes preguntas:
1. ¿Qué estrategias de ventas y marketing farmacéutico...


Página 1 de 2